Determine The Percentage Of Depressed Outpatients Who Do Not Effectively Metabolize Extended-release Venlafaxine HCl

Inclusion Criteria

• •Men and women subjects aged 18 years or older.
• •Current outpatient treatment with extended-release venlafaxine HCl (U.S. marketed brand Effexor XR®), within the US Food and Drug Administration (FDA)-approved dosage range for depression (37.5 mg/day to 225 mg/day), for 8 weeks or less.
• •Ability to have a blood draw within 4 to 12 hours of the most recent dose of Effexor XR®.